Navigation Links
Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
Date:6/2/2008

PITTSBURGH, June 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it has acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic. As announced previously, Mylan exercised its option to acquire these businesses as part of the original, October 2007 agreement in which Mylan acquired Merck KGaA's generics business (Merck Generics) in Western Europe, Asia-Pacific, Africa and North America.

The acquisition does not require any additional consideration from Mylan to Merck KGaA, Mylan said.

"Our acquisition of the CEE businesses gives us access to an additional area with significant growth opportunities for generics," said Mylan Vice Chairman and CEO Robert J. Coury. "It reflects our global strategy to leverage existing platforms, rather than create start-up organizations. In that respect, we believe the CEE businesses will benefit significantly from Mylan's scale, vertical and horizontal integration, and robust product portfolio."

"My team and I are excited to have back the CEE businesses, which I helped establish when I was a part of the Merck Generics organization," said Didier Barret, president of Mylan Europe, Middle East and Africa. "We're eager to continue to build upon our pan-European presence and execute the growth strategies we've always had in mind for this region."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

This press release contains statements that constitute "forward-looking statements", including with regard to Company's expected opportunities and growth potential and the anticipated benefits to the CEE businesses from Mylan's integrated platform. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges and costs relating to integration of the businesses; the effect of any changes in customer and supplier relationships and customer purchasing patterns; general market perception of the transaction; the ability to attract and retain key personnel; changes in economic and financial conditions of the Company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the Form 10-Q for the quarter ended March 31, 2008, and the other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... Cypress in Sun City is the place to be on March 3rd to learn about ... will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will ... offers. In addition, prizes will be given away and light refreshments will be served. ...
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from Pixel Film Studios ... Cut Pro X. Each user can select from up to 40 effect overlays. With ... focus offset, hue, saturation, value, contrast, glow, and more all within a click of ...
(Date:2/13/2016)... Lake City, Utah (PRWEB) , ... February 13, 2016 , ... When an Au ... Host Parents aren’t always sure what they are in for and they are often worried ... are more than they were hoping for. This year’s Au Pair of the Year winner’s ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips ... biography of Rama - Dr. Frederick Lenz. , According to Publisher Roger ... Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love in all ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Maharashtra, February 12, 2016 ... report titled Chronic Inflammation Global Clinical Trials Review, ... of the global clinical trials landscape along with ... by Region, Country (G7 & E7), Trial Status, ... and reviews top companies involved and enlists all ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
(Date:2/11/2016)... 11, 2016 Potrero Medical, Inc., the developer of ... the appointment of George M. Rapier, III , MD, ... TX , WellMed is one of the nation,s largest ... HMO members in Texas and ... of his own internal medicine practice, he has been instrumental ...
Breaking Medicine Technology: